目的　探讨DNA免疫吸附治疗用于妊娠合并系统性红斑狼疮 (SLE)患者的临床效果。方法　对 6 9例妊娠合并SLE患者随机进行免疫吸附治疗 35例 (治疗组 )和常规治疗 34例 (对照组 )。将治疗组的动脉血流经DNA免疫吸附剂 (罐 ) ,然后由静脉回输至体内。比较两组的妊娠结局和并发症发生情况。结果　妊娠并发症 [妊娠高血压综合征 (妊高征 )、胎盘功能不全、流产等 ]发生率 :治疗组为 2 8 6 %、对照组为 85 3% ,两组比较 ,差异有极显著性 (P <0 0 1) ;胎儿丢失率 :治疗组为 2 0 0 %、对照组为 5 8 8% ,两组比较 ,差异有极显著性 (P <0 0 1)。早产儿发生率 :治疗组为 8 6 %、对照组为2 6 5 % ,两组比较 ,差异有显著性 (P <0 0 5 )。结论　DNA免疫吸附治疗妊娠合并SLE ,临床效果优于常规治疗 Objective To investigate the clinical effect of DNA immunosorbent assay (ELISA) in patients with pregnancy complicated with systemic lupus erythematosus (SLE). Methods Sixty-nine patients with pregnancy complicated with SLE were randomly divided into 35 cases (treatment group) and 34 cases (control group). Arterial blood from the treated group was passed through a DNA immunoadsorbent (canister) and then intravenously to the body. The pregnancy outcomes and complications of the two groups were compared. Results The incidence of pregnancy complications [pregnancy-induced hypertension syndrome (PIH), placental insufficiency, abortion, etc.] incidence: the treatment group was 286%, 85.3% in the control group, the two groups, the difference was significant (P <0.01). The rate of fetal loss was 200% in the treatment group and 58.8% in the control group. There was a significant difference between the two groups (P <0.01). The incidence of preterm birth was 86% in the treatment group and 26.5% in the control group. There was significant difference between the two groups (P <0.05). Conclusion DNA immunosorbent for the treatment of pregnancy complicated with SLE, the clinical effect is superior to conventional treatment